// Biotech and Pharma Therapeutics
Caught Between Visits: How Our System Fails People With Parkinson’s and Dementia
September 3, 2025 / Parkinson’s care / dementia support / chronic disease / neurology gap / patient tracking
Current healthcare systems fail patients with Parkinson’s and dementia by lacking continuous, personalized support. Better outcomes require real-time symptom tracking, team-based care, and integrating patients and caregivers as active partners in long-term disease management.
3 medtech takeaways from ESC 2025
September 3, 2025 / pulsed field ablation / atrial fibrillation / Navitor valve / aortic stenosis / ESC 2025
ESC 2025 highlighted promising real-world results for J&J’s Varipulse PFA system, demonstrated PFA’s safety edge over RFA in atrial fibrillation, and supported expanded use of Abbott’s Navitor valve for lower-risk aortic stenosis patients in Europe.
Pretzel strengthens leadership team with new CDO
September 3, 2025 / Pretzel Therapeutics / POLG inhibitor / mitochondrial disorders / neurodegenerative diseases / clinical development
Pretzel Therapeutics appoints Ashish Dugar as Chief Development Officer to lead clinical development, coinciding with the launch of its first trial for PX578, a therapy targeting POLG in mitochondrial and neurodegenerative disorders.
Edwards, Medtronic and Abbott stand to benefit from new TAVR guidelines in Europe
September 3, 2025 / TAVR guidelines / aortic stenosis / Edwards Lifesciences / asymptomatic patients / heart valve replacement
New European guidelines lower the TAVR age threshold to 70 and strengthen recommendations for asymptomatic patients, potentially expanding access and benefiting Edwards, Medtronic, and Abbott—especially Edwards, which holds the only approved system for asymptomatic use.
India launches national biomanufacturing hubs to propel bioeconomy
September 3, 2025 / India biomanufacturing / API production / BioE3 policy / biotechnology hubs / pharma self-reliance
India’s BioE3 policy launches national biomanufacturing hubs to boost domestic production of APIs, fermentation-based drugs, and enzymes, aiming to reduce import dependence and strengthen its bioeconomy for healthcare, environment, and employment growth.
// 4th Industrial Revolution
How AI advances will shape the drugmaker of the future
September 2, 2025 / AI drug discovery / machine learning pharma / precision medicine AI / AI clinical development / biotech innovation
AI is revolutionizing drug development by accelerating target discovery, improving precision medicine, and enabling faster, data-driven decisions. Pharma leaders foresee AI reshaping R&D processes, reducing failure rates, and enhancing treatment personalization across cardiometabolic, immunological, and neurodegenerative diseases.
Easing Frontline Pressure: How AI Can Lift the Administrative Burden Off Care Teams
September 3, 2025 / AI healthcare burnout / agentic AI medicine / clinical automation tools / medical administrative burden / AI patient follow-up
Agentic AI can reduce clinician burnout by automating administrative tasks like insurance authorization and post-op follow-ups. When implemented transparently and with oversight, these systems help restore clinical focus without compromising safety or empathy in patient care.
Onvida Health and Ambience Healthcare Launch Ambient AI Integration with Epic
September 3, 2025 / ambient AI Epic / clinical documentation automation / Epic integration AI / AI medical coding / ambient scribing healthcare
Onvida Health and Ambience Healthcare have integrated ambient AI tools into Epic’s Hyperspace and Haiku apps, streamlining documentation, coding, and compliance support across 200+ specialties, significantly reducing clinician burden while enhancing accuracy and workflow efficiency.
Medable Launches Agent Studio, the First Agentic AI Platform for Life Sciences
September 3, 2025 / agentic AI trials / Medable Agent Studio / AI clinical research / CRA AI platform / clinical trial automation
Medable has launched Agent Studio, the first agentic AI platform for life sciences, enabling clinical teams to build custom AI agents that streamline clinical trial operations, reduce inefficiencies, and accelerate drug development with human-in-the-loop oversight and regulatory alignment.
PurpleLab Acquires KAID Health to Create AI-Powered Healthcare Intelligence Platform
September 3, 2025 / healthcare AI platform / PurpleLab KAID acquisition / clinical data integration / NLP medical analytics / value-based care
PurpleLab has acquired KAID Health to merge large-scale structured claims data with AI-powered unstructured data analysis, enabling a unified platform that enhances coding accuracy, care management, research, and value-based care through deeper clinical insights.
// Business & Markets
Gilead’s Kite erodes $2.3B off-the-shelf cell therapy deal with Shoreline
September 3, 2025 / cell therapy partnership / Gilead Kite Shoreline / off-the-shelf CAR-T / natural killer cells / cancer immunotherapy deal
Gilead’s Kite Pharma has ended its $2.3B off-the-shelf cell therapy collaboration with Shoreline Biosciences, which focused on natural killer cell engineering for cancer. Despite this, Kite remains active in cell therapy with new acquisitions like Interius BioTherapeutics.
Reconditioned pacemakers show comparable infection rates to new devices
September 3, 2025 / reconditioned pacemakers safety / cardiac device reuse / low-income cardiac care / pacemaker infection rates / global heart health
A multicountry trial found that reconditioned pacemakers, cleaned and tested under a strict protocol, have comparable infection rates and safety to new devices. This supports their use in low-resource settings to expand global access to life-saving cardiac care.
Wave RNA editing restores enzyme in genetic condition but underwhelms investors
September 3, 2025 / RNA editing / alpha-1 antitrypsin / AATD therapy / Wave Life Sciences / genetic liver disease
Wave Life Sciences’ RNA-editing therapy WVE-006 showed clinically meaningful restoration of alpha-1 antitrypsin levels in AATD patients, with a favorable safety profile. Despite meeting therapeutic targets, investor response was muted due to modest improvement over previously reported data.
Novartis returns to Argo for multifaceted $5B cardiovascular collab
September 3, 2025 / Novartis / siRNA therapeutics / cardiovascular collaboration / dyslipidemia treatment / Argo Biopharma
Novartis has expanded its cardiovascular collaboration with Argo Biopharma, investing $160M upfront for rights to siRNA therapies targeting dyslipidemia and hypertriglyceridemia, with total deal value exceeding $5B. The partnership supports global development of novel RNAi-based treatments.
Eisai moves swiftly to expand subcutaneous Leqembi label
September 3, 2025 / Alzheimer’s treatment / subcutaneous Leqembi / Eisai Biogen collaboration / home injection therapy / lecanemab approval
Eisai has initiated a rolling BLA to expand use of subcutaneous Leqembi Iqlik for Alzheimer’s, aiming to allow at-home treatment from therapy onset. The move may improve accessibility and reduce clinic burden compared to IV administration.
// Legal & Regulatory
Biohaven’s rare disease drug is ‘ready to ship on Day 1’ following FDA approval
September 3, 2025 / spinocerebellar ataxia / rare disease treatment / Vyglxia approval / Biohaven launch / FDA neurology drug
Biohaven is prepared to launch Vyglxia, an oral therapy for spinocerebellar ataxia, immediately upon expected FDA approval. If approved, Vyglxia will be the first approved treatment for this rare neurodegenerative condition, targeting roughly 15,000 U.S. patients.
FDA panels, politics and power: the shifting balance
September 3, 2025 / FDA advisory panels / drug approval politics / regulatory transparency / expert committees FDA / medicine decision-making
FDA advisory panels have long guided drug approval decisions, but recent political shifts and high-profile divergences from panel recommendations raise questions about their current influence on regulatory outcomes and public trust.
FDA Advances Rare Disease Drug Development with New Evidence Principles
September 3, 2025 / rare disease drugs / FDA approval process / RDEP guidance / genetic therapies FDA / small population trials
The FDA introduced the Rare Disease Evidence Principles (RDEP) to guide drug developers targeting ultra-rare genetic diseases, allowing flexible, evidence-based approval pathways using alternative data sources when traditional trials are impractical due to small patient populations.
Analyst questions impact of FDA’s rare disease pathway proposal
September 3, 2025 / rare disease FDA / RDEP pathway review / genetic therapy approval / single-arm trial drugs / ultrarare disease treatment
The FDA’s Rare Disease Evidence Principles (RDEP) aims to streamline approval for therapies targeting ultrarare genetic diseases using single-arm trials plus supportive evidence. Analysts question its real-world impact, as many gene therapies already follow similar regulatory paths.
Real-time drug pricing access rule to take effect
September 2, 2025 / real-time drug pricing / CMS prior authorization / prescription transparency rule / healthcare IT regulation / Medicare prescription reform
Starting Oct. 1, a CMS rule will require providers to use certified health IT for real-time drug pricing, coverage, and prior authorization checks, aiming to reduce administrative burden and improve decision-making at the point of care.
// Research & Development
Novel ablation approach improves outcomes in patients with persistent atrial fibrillation
September 3, 2025 / atrial fibrillation treatment / digital twin ablation / ESC Congress 2025 / personalized cardiac therapy / PVI clinical trial
Digital twin-guided ablation combined with standard pulmonary vein isolation significantly improved arrhythmia-free survival in patients with persistent atrial fibrillation, without increasing complications or procedure time, according to results from the CUVIA-PRR trial presented at ESC Congress 2025.
Pfizer, Valneva boosted by updated vaccine data ahead of moment in the Lyme-light
September 3, 2025 / Lyme disease vaccine / Pfizer Valneva VLA15 / phase 2 booster data / seroconversion rates Lyme / Lyme disease prevention
Valneva and Pfizer’s Lyme disease vaccine candidate VLA15 showed strong, consistent antibody responses across all age groups after a third booster dose, with 100% seroconversion and no safety concerns—supporting potential annual boosters ahead of a 2026 regulatory filing.
Metformin’s mysterious metal effect could explain its big health benefits
September 3, 2025 / metformin metal levels / diabetes drug mechanism / copper iron zinc / metformin health benefits / Kobe University study
A Kobe University study found that metformin alters blood metal levels—reducing copper and iron, while increasing zinc—which may explain its wide-ranging benefits beyond blood sugar control, such as reduced inflammation and cancer risk, offering insight for future diabetes drug design.
A refresher on research around Tylenol while pregnant
September 3, 2025 / CDC vaccine changes / childhood immunization schedule / Robert Kennedy Jr CDC / vaccine policy controversy / CDC leadership resignations
The CDC’s vaccine advisory committee may propose changes to childhood immunization schedules amid leadership upheaval, raising concerns among experts that new policies could diverge from established scientific consensus under recently appointed officials aligned with political interests.
Merck & Co’s PCSK9 inhibitor lowers cholesterol and raises hopes
September 3, 2025 / Merck PCSK9 inhibitor / enlicitide cholesterol trial / CORALreef Lipids study / LDL-C reduction drug / oral hypercholesterolemia treatment
Merck’s oral PCSK9 inhibitor, enlicitide decanoate, significantly reduced LDL cholesterol in the Phase III CORALreef Lipids trial, meeting all primary and key secondary endpoints in patients with hypercholesterolemia or statin intolerance.
// Politics
Over 1,000 HHS workers call for RFK Jr. to step down
September 3, 2025 / HHS controversy / RFK Jr. resignation / vaccine policy crisis / public health leadership / CDC staff departures
Over 1,000 HHS employees are demanding HHS Secretary Robert F. Kennedy Jr.’s resignation, citing anti-science policies, disruption to vaccine programs, and leadership turmoil, which they argue undermine public health and jeopardize trust in U.S. healthcare systems.
7 burning questions for RFK Jr. as he faces senators on CDC turmoil and more
September 3, 2025 / RFK Jr. testimony / CDC leadership crisis / vaccine funding cuts / mRNA research halt / public health controversy
HHS Secretary Robert F. Kennedy Jr. will testify before Congress amid backlash over his CDC leadership overhaul, vaccine funding cuts, and mRNA research halts—moves critics say endanger U.S. public health and prompt widespread calls for his resignation.
Washington, Oregon and California governors form a health alliance in rebuke of Trump administration
September 3, 2025 / CDC restructuring / anti-vaccine policies / COVID-19 alliance / public health crisis / West Coast governors
In response to CDC restructuring and anti-vaccine policies under the Trump administration, the governors of California, Oregon, and Washington have formed a health alliance to uphold science-based public health policy amid rising COVID-19 cases and leadership turmoil.
RFK Jr. critic Paul Offit iced out of key FDA vaccine panel
September 3, 2025 / FDA panel / vaccine expert / RFK Jr. controversy / public health policy / advisory committee
Vaccine expert Dr. Paul Offit has been removed from the FDA’s key vaccine advisory panel amid administrative delays and political tension with HHS Secretary RFK Jr., raising concerns over expert exclusion and politicization of U.S. vaccine policy oversight.
Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize
September 3, 2025 / COVID vaccine / Pfizer defense / Operation Warp Speed / vaccine transparency / RFK Jr. policies
Pfizer defended the scientific integrity of its COVID-19 vaccine, citing over 600 peer-reviewed studies, while CEO Albert Bourla supported former President Trump’s Operation Warp Speed and Nobel Prize eligibility amid rising political scrutiny and public vaccine skepticism.